6. Dupixent


Companies: Sanofi, Regeneron
Used for: Atopic dermatitis, asthma, chronic rhinosinitus with nasal polyps. 
2019 sales: $2.32 billion

Sanofi and Regeneron's long-standing antibody partnership saw some big changes early this year when the pair agreed to rework their deal moving ahead. But one thing won't change: a joint commercial agreement for immunology med Dupixent, which both drugmakers see as a cash cow on the near horizon. 

Dupixent could add $1.08 billion to its 2019 sales of $2.32 billion, according to EvaluatePharma. That would bring the blockbuster drug's sales this year up to $3.4 billion. 

Sporting a label update after an FDA approval to treat chronic rhinosinitus with nasal polyps, Dupixent is well set to grow its sales in the coming year in a lucrative—and increasingly competitive—eczema market. 

RELATED: Sanofi's sunny forecast for Dupixent and its aging diabetes drugs just might be achievable: analyst

6. Dupixent